Top

Published in:

01-12-2020 | Hematology | Correction

Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

Authors: Giulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, Caterina Vivaldi, Oronzo Brunetti, Luca Ielasi, Fabio Conti, Giulia Rovesti, Laura Gramantieri, Mario Domenico Rizzato, Irene Pecora, Antonella Argentiero, Federica Teglia, Sara Lonardi, Francesca Salani, Alessandro Granito, Vittorina Zagonel, Giorgia Marisi, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Francesca Benevento, Alessandro Cucchetti, Fabio Piscaglia, Stefano Cascinu, Mario Scartozzi, Andrea Casadei-Gardini

Published in: Targeted Oncology | Issue 6/2020

Excerpt

An Online First version of this article was made available online at https://link.springer.com/article/10.1007/s11523-020-00757-3 on 12 October 2020. Errors were subsequently identified in the article, and the following corrections should be noted. …

Title: Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
Authors: Giulia Orsi
Francesco Tovoli
Vincenzo Dadduzio
Caterina Vivaldi
Oronzo Brunetti
Luca Ielasi
Fabio Conti
Giulia Rovesti
Laura Gramantieri
Mario Domenico Rizzato
Irene Pecora
Antonella Argentiero
Federica Teglia
Sara Lonardi
Francesca Salani
Alessandro Granito
Vittorina Zagonel
Giorgia Marisi
Giuseppe Cabibbo
Francesco Giuseppe Foschi
Francesca Benevento
Alessandro Cucchetti
Fabio Piscaglia
Stefano Cascinu
Mario Scartozzi
Andrea Casadei-Gardini
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Hematology
Sorafenib
Published in: Targeted Oncology / Issue 6/2020
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-020-00765-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2020

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer

Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study

Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry

Keynote webinar | Spotlight on antibody–drug conjugates in cancer